Nivolumab Versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy (Attraction-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial

Research paper from The Lancet curated by Editor in Chief George Lundberg, MD, who notes: 

In this clinical trial, nivolumab was somewhat superior to chemotherapy for advanced esophageal carcinoma.

Go to full paper published in The Lancet.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.